Don't Miss Our New Year's Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Syncona Shs GBP ( (GB:SYNC) ) has issued an update.
Achilles Therapeutics, a company within Syncona’s investment portfolio, announced the sale of its technology assets to AstraZeneca for $12 million. The transaction, which includes the transfer of a commercial license for data and samples from the TRACERx lung cancer study and Achilles’ Material Acquisition Platform, marks the completion of Achilles’ strategic review initiated in September 2024. Following the sale, Achilles plans to reduce its workforce and board size, which could impact its operational structure, while Syncona’s holding in Achilles remains a small fraction of its total Net Asset Value.
More about Syncona Shs GBP
Syncona Limited is a prominent life science investor dedicated to creating, building, and scaling a portfolio of global leaders in life sciences. The company focuses on developing transformational treatments in areas of high unmet need by partnering with academic founders and experienced management teams. Syncona aims to build a diversified portfolio of life science businesses to deliver patient impact and strong risk-adjusted returns to shareholders.
YTD Price Performance: -16.86%
Average Trading Volume: 747,960
Technical Sentiment Consensus Rating: Buy
For detailed information about SYNC stock, go to TipRanks’ Stock Analysis page.
